NEW YORK (GenomeWeb News) — The US Federal Trade Commission has cleared Agilent Technologies’ proposed acquisition of Stratagene, according to a notice on the FTC’s website.
 
Agilent in April offered to buy Stratagene for $246 million, or $10.94 per share.
 
At the time, Stratagene CEO Joseph Sorge said he plans to form a new company that will pay $6.6 million for some of Stratagene’s molecular diagnostics assets.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.